STAT4 polymorphism, rs7574865 is linked to various autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Its T minor allele is associated with higher STAT4 mRNA and protein expression, indicating a stronger skewed immune response than the norm. Although widely studied in autoimmune disease patients and the general population, its effect on immunocompromised subjects is still unknown. Especially in situations, i.e. post-hematopoietic stem cell transplantation (post-HSCT), where control of the immune response is crucial. Hence, this study investigates if the presence of the T minor allele in donors would affect immunological response and clinical outcomes post-HSCT. Samples from 161 pediatric patients who underwent allogeneic HSCT for acute leukemia and showed complete chimerism by donor cells were obtained. Six clinical outcomes were investigated; hepatic veno-occlusive disease, acute graft-vs-host disease, chronic graft-vs-host disease, cytomegalovirus (CMV) infection, relapse and overall survival. The TT genotype was found to be significant in the occurrence of CMV infection (P = 0.049), showing higher incidence of CMV infection compared to the others. Multivariate analysis confirmed that association of the TT genotype is independent from other variables in CMV infection occurrence (P = 0.010). This is the first study on STAT4 polymorphism rs7574865 in allogeneic HSCT as well as immunocompromised patients. As the TT genotype is associated with autoimmune diseases, our results seem at a paradox with current evidence hinting at a different role of STAT4 in normal circumstances versus immunocompromised patients. Further investigation is needed to elicit the reason behind this and discover novel applications for better post-transplant outcomes.
Introduction
Signal transducer and activator of transcription 4 (STAT4) is a member of the JAK-STAT pathway which is a vital signaling pathway in the immune response. The STAT protein is phosphorylated by Janus kinase (JAK) receptors on the cell surface after cytokine activation and translocates into the nucleus to initiate transcription of target genes [1] . It is the only tissue-specific STAT, expressed in myeloid and lymphoid tissues and has most commonly been associated with the regulation of interleukin-12 (IL-12) and its biological functions [2] . IL-12 binds specifically to two receptor subunits expressed on natural killer (NK) cells and activated B and T cells [3] . It is responsible for the production of IFN-γ, monocyte activation and T-helper type 1 (T H 1) cell differentiation [4] .
Therefore it is a critical mediator of the immune response and it is highly plausible that any change in STAT4 activity or expression can alter the function and response of the immune system, leading to autoimmune disorders or immunosuppression.
As a matter of fact, many STAT4 polymorphisms have increasingly been associated with systemic autoimmune diseases such as systemic lupus erythematosus (SLE) [5] , rheumatoid arthritis (RA) [6] etc. in various populations [7] [8] [9] [10] . In particular, evidence has pointed to the presence of polymorphism rs7574865 G/T as having the strongest associations. The presence of the T allele showed significant increase in odds ratio for SLE, RA, type 1 diabetes (T1D), Systemic Sclerosis (SSc) and Primary Sjogren's Syndrome (pSS) [11] and possibly associated with Juvenile Idiopathic Arthritis (JIA) and Primary Antiphospholipid Syndrome (APS) [12, 13] . In addition, the TT genotype has been proven to increase susceptibility to autoimmune thyroid diseases (AITD) [14] . Its minor T allele has also been proven to be associated with acute renal allograft rejection [15] , further implying a significant role in the immune response. Therefore we looked into the possibility of an association of the rs7574865 G/T polymorphism with other transplant outcomes as well, especially in hematopoietic stem cell transplant (HSCT).
Materials and methods

Study population
The study population consisted of pediatric patients with acute leukemia who underwent hematopoietic stem cell transplantation between November 2001 and April 2014 in the Seoul National University Children's Hospital. Out of 279 patients who underwent HSCT in this period, only 201 showed chimerism with donor cells. Out of this 201, only 161 produced viable DNA samples from HLA-matched transplants, resulting in a final of 161 patient samples used in this study. Peripheral blood or bone marrow aspiration samples were collected after the transplantation procedure and stored in the human-derived sample storage facility. DNA was then isolated and analyzed from each sample. Samples used met the following inclusion criteria: (i) pediatric patients who were diagnosed with acute leukemia and received allogeneic-HSCT (allo-HSCT); (ii) post-transplant samples showed complete chimerism of hematopoietic cells by donor cells (short tandem repeat (STR) test on patients' DNA b 0.8%). Out of the available samples, 161 suitable samples were analyzed.
This study was designed in accordance with the regulations for research involving human subjects and approved by the Institutional Review Board for Human Research (IRB number: 1512-061-728).
Transplantation protocol
Before 2005, donors were selected based on human leukocyte antigen (HLA) serologic typing performed for class I antigens and HLA molecular typing for the DR loci. From 2006 onwards, typing for the DQ loci was included. HLA-A,-B, -C, -DR, -DQ were confirmed through a highresolution molecular method for both recipients and donors.
Bu-based and TBI-based conditioning regimens were carried out to prepare patients for transplant. Graft-vs-host disease (GvHD) prophylaxis consisted of cyclosporine and prednisolone for related HSCT, cyclosporine and mycophenolate mofetil for cord blood therapy (CBT) or tacrolimus and methotrexate for unrelated bone marrow (BM) or peripheral blood (PB) stem cell transplantation. Hepatic veno-occlusive disease (HVOD) and infection prophylaxis were administered according to our center guidelines for HSCT. For HVOD prophylaxis, patients received lipo-PGE1 at a dose of 1 mcg/ kg/day through continuous infusion with or without low molecular heparin (nadroparine calcium). For infection prophylaxis, patients received ciprofloxacin, itraconazole, or micafungin, and acyclovir. Intravenous immune globulin (0.5/g/kg/dose) was infused every two weeks until Day 100, then monthly until Day 180. Sulfamethotrexate/trimethoprim was discontinued three days before HSCT and restarted after engraftment.
Chimerism analysis
Serial analysis of STR in BM aspirates were performed to evaluate the hematopoietic chimerism in patients at 1, 3, 6 months and 1 year after the allo-HSCT, excluding patients who underwent CBT. Patients who underwent CBT had the chimerism analysis carried out more frequently beginning at 1, 2 and 3 weeks from peripheral blood and 1, 3, 6 months and 1 year from BM aspirate. The chimerism analysis was based on the quantitative amplification of specific STR regions in the patient and donor by using an AmpFISTR profiler polymerase chain reaction (PCR) amplification kit (Applied Biosystems, Foster City, CA, USA).
SNP analysis
DNA was extracted from the samples by using the QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA purity and concentration were determined by spectrophotometric measurements using absorbance levels at 260 nm and 280 nm. The extracted genomic DNA was stored at −20°C before analysis for its genotype. The upstream primer sequence used was 5′-AAA GAA GTG GGA TAA AAA GAA GTT TG-3′ and the downstream primer sequence 5′-CCA CTG AAA TAA GAT AAC CAC TGT-3′ to generate a 147 base pair region of the STAT4 polymorphism, rs7574865 [15] . The polymerase chain reaction (PCR) was carried out on a Bio-Rad MyCycler™ Thermal Cycler . A total reaction volume of 30 μl containing 200 ng genomic DNA template, 20 pmol of each primer was added into a PCR pre-mix (Solg™ 2 × Taq PCR Pre-Mix, SolGent, Daejeon, Korea). The amplification profile was as follows: 95°C for 2 min, followed by 40 cycles of 95°C for 20 s, 61°C for 40 s and 72°C for 60 s, with a final cycle of extension at 72°C for 5 min. In addition, tubes containing all the same PCR components but with the DNA template replaced with distilled water served as negative controls to ensure that there was no contamination of DNA carried over from prior reactions. 2 μl of each PCR products was then ran on agarose gel to check for successful replication of the 147 bp product. The remaining 28 μl was purified with a PCR purification kit (QIAquick® PCR Purification Kit, QIAGEN, Hilden, Germany), according to the manufacturer's instructions, to a volume of 30 μl. 15 μl of the purified product was incubated with a three times excess in units of Hpa I restriction enzyme (RE) (Takara Bio Inc., Otsu, Japan) for 90 min at 37°C. This RE specifically recognises and digests DNA amplified from the minor allele (T) into 122 bp and 25 bp products. Therefore GG homozygous individuals will show only 147 bp bands, GT heterozygous individuals bands of both 147 bp and 122 bp while homozygous TT individuals show only the 122 bp band. Reaction mixtures using distilled water in place of the REs were used as negative controls while mixtures using a known TT genotype DNA sample was used as positive controls. Both undigested and digested PCR products were visualised in 2.5% agarose gel stained with StaySafe™ Nucleic Acid Gel Stain (Real Biotech Corporation, Taipei, Taiwan). Genotypes were scored blindly and all ambiguous samples repeated.
Definitions
The diagnosis of HVOD was made based on the modified Seattle criteria [16] , acute graft-versus-host disease (aGvHD) and chronic graft-versus-disease (cGvHD) according to their respective standard criteria [17, 18] . Cytomegalovirus (CMV) infection was defined as the presence of CMV pp65 antigen positive cells at a frequency of ≥ 1/ 2 × 10 5 cells. CMV disease was diagnosed through histopathological examinations or ophthalmoscopy exam showing characteristic retinal changes.
Statistical analysis
Statistical calculations were performed with SPSS statistical software version 23.0 for Mac (SPSS Inc., Chicago, IL, USA) and R statistical software version 3.2.3 for Mac. The Kaplan-Meier method and Log-rank test were used for univariate survival analysis. Cumulative incidences (CI) were analyzed with the Gray test. Competing events were defined as death without HVOD for HVOD; death without CMV infection for CMV infection; death without aGvHD for aGvHD and death without cGvHD for cGvHD. Factors that showed a statistically significant difference upon univariate analysis were included in the multivariate analysis. All tests were two tailed and a statistical value of P b 0.05 was considered to be significant.
Results
Rs7574865 genotyping
161 patient samples were analyzed for the rs7574865 polymorphism genotype. 78 (48.4%) patients were found to have the homozygous GG genotype, 69 (42.9%) had the heterozyous GT phenotype while 14 (8.7%) had the homozygous TT genotype. This is in consensus with the population average of about 10% for the TT genotype [14, 19] . This along with other baseline and demographic clinical characteristics of patients involved in the study are listed in Table 1 .
Cumulative incidence
The influence of the genotypes was compared in six outcomes; HVOD, CMV infection, aGvHD, cGvHD, relapse and survival. When comparing the three genotypes (GG, GT and TT) individually, no statistically significant difference was observed (Fig. 1) . Then, the GG and GT genotypes were combined and compared against the TT genotype (Fig. 2) . In the case of CMV infection, the TT genotype was found to significantly affect disease occurrence compared to the GG and GT group (P = 0.05). Previous studies have also shown that the source of stem cells for transplantation may have an impact on certain outcomes [20, 21] . Therefore, we investigated the significance of the target genotype for CMV infection in each of the three different stem cell sources (Fig. 3) . Results show that the TT genotype has a significant influence on CMV infection after transplantation from cord blood (P = 0.01) but does not affect those with bone marrow or peripheral blood as stem cell sources. No statistically significant results were observed for HVOD, aGvHD, cGvHD, relapse or survival in the patients but a general trend where the TT genotype shows a lower rate of disease occurrence and higher overall survival is observed. Table 2 shows a multivariate analysis to identify predictors of CMV infection through the Cox regression model. The analysis was used to determine the influence of rs7574865 and other clinical variables (gender, age, disease, pre-SCT status, donor type, conditioning regime and CMV prophylaxis) on its occurrence after significance was found in univariate analysis. It supports the results shown in the previous figures, identifying the rs7574865 TT genotype as a risk factor for CMV infection (P = 0.03), with carriers twice as likely as the GG and GT group to contract CMV infection. Current research has also shown that donor CMV seropositivity can be a risk factor for CMV infection [22, 23] , hence the donor CMV IgG status was also investigated in this experiment. However, only 9% of the donors was confirmed to be IgG-negative, with the majority of the donors showing seropositivity. Therefore, its influence on CMV infection does not undermine the significance of the influence from the TT genotype. The multivariate analysis shows that except for the rs7574865 polymorphism, other clinical variables did not influence CMV infection.
Determination of rs7574865 as CMV risk factor through multivariate analysis
Discussion
HSCT is now the common practice in the treatment of congenital or acquired hematologic malignancies or immunological disorders [24] . However, the success of HSCT hinges on the careful balance of the donor immune response to elicit a Graft vs Tumor effect [25] while keeping the recipient's immune response carefully in check to prevent GvHD and rejection of the graft but minimise the risk of infections [26] . Hence research on changes that can occur in an individual's immune response stands to benefit increasing the success of HSCT. The study is focused specifically on the rs7574865 polymorphism due to its increasing popularity in recent immunology studies. As mentioned previously, the polymorphism has influence in various immunological diseases but as it is found in the third intron of the gene, its relation with protein function is yet unknown. A recent study on the polymorphism has shown higher sensitivity to IFN-γ, an inflammatory cytokine which is involved in signaling of the immune response [27] . The T allele has also been associated with higher STAT4 mRNA and protein levels [28] . STAT4 is crucial for the initiation and maintenance of the immune and inflammatory responses [29] . Our findings suggest that donor TT genotype from rs7574865 G/T polymorphism may affect the immune response of recipients and hence influence the success of HSCT.
To our knowledge, this is the first study of a STAT4 polymorphism in HSCT, in immunocompromised patients and in pediatrics. In our study, we assessed the potential influence of the presence of the rs7574865 minor T allele in donor cells on the clinical outcomes of patients postaHSCT. Out of the six outcomes investigated, the T minor allele was found to be significantly associated with the occurrence of CMV infection. Although no statistical significance was noted, the increase in CMV infection and the lower occurrence of unfavourable outcomes (lower incidences of aGvHD, cGvHD and relapse with higher incidence of overall survival) in the TT genotype seem to indicate a possible weaker immune response in this genotype compared to the others. This seemingly appears as a contradiction to current knowledge of this polymorphism yet reports showing similar paradoxes have also been reported. Rs7574865 has been reported to be linked to a predisposition to SLE as well as increased STAT4 mRNA and protein expression which theoretically leads to a stronger immune and/or inflammation response. Yet a report by Singh et al. shows accelerated nephrititis in STAT4-deficient lupus mice models [30] . Chaim et al. showed that STAT4 deficiency accelerated kidney disease and led to higher mortality for SLE but lower levels of autoantibodies were observed compared to the wildtype [31] . Additionally, a study by Shin et al. found that CMV infection and aGvHD occurrence showed differential expression in suppressors of cytokine signaling (SOCS) proteins [32] . As SOCS proteins function via the Jak/STAT pathway, the difference in expression of immune regulatory molecules gives support to the results found in our study. Hence, these reports suggest that more detailed research is needed to ascertain the role of STAT4 in the progression of various diseases as well as to fully determine its capacity and its mechanism of action in an immune response. The lower incidences of negative outcomes (i.e. occurrence of GvHD and relapse) also bring to question the graft vs leukemia effect of this polymorphism and is an area of interest for future research. In addition, some factors of this study should be noted when reviewing the results. For example, Fig. 3 shows statistical significance of the TT genotype for CMV infection in cord blood but not in peripheral blood or bone marrow. To our knowledge, the congenital cord blood infection rate in Korea is only 1.5% [33] and hence is unlikely that the results were due to cord blood cells carrying CMV infection prior to transplant. However, CMV infection has been found to be highly prevalent in Korea (N 90%) [34] . Hence most donors would have been exposed to and developed an immunity to CMV. When performing transplant with bone marrow or peripheral blood, the recipient inherits this immunity from the donor's immune cells and is less likely to develop CMV infection [35] . In cord blood transplants however, the donor cord blood has not been exposed to the CMV virus and hence has lower immunity and higher susceptibility to CMV infection [36] .
Another factor that should be accounted for is the setting in which this experiment was carried out. Previous research has been focused on the role of the polymorphism in patients with autoimmune diseases while comparing to the general population. In our experiment, we looked at the effects of this polymorphism on HSCT patients who are medically immunocompromised. Studies have shown that many commonly used drugs in cancer treatment such as glucocorticoids, i.e. dexamethasone [37] , and chemotherapy [38] inhibit STAT4 phosphorylation and result in acquired STAT4 deficiency respectively. This does not affect the results of our experiment as patients undergo similar regimens and hence does not pose as a problem when comparing within the sample. However, these discrepancies with the general population indicate that any comparison or translation of the results to other studies must be handled with caution. As the mechanism of the polymorphism is yet unknown, the possibility that the minor T allele has a higher susceptibility to these drugs and treatment is also another factor that must be considered. In addition, this is the first study of STAT4 polymorphism in children, more research has to be done to see if similar results can be found in adults.
In conclusion, our research sheds light on the importance and impact of donor STAT4 polymorphisms in transplant recipients and its correlation on transplantation outcomes. It highlights the significance of understanding the role of STAT4 in the immune response to increase the success of HSCT. Medication that affects STAT4 expression is already attainable (i.e. dexamethasone which inhibits STAT4 phosphorylation therefore inhibiting T H 1 response [37] ), but its role is still very limited. This study therefore also hopes to introduce novel drug development targets for STAT4-related diseases. Fig. 3 . Cumulative incidence of CMV infection, according to the stem cell source, in patients with the G allele compared with homozygous T allele genotype from donors. A denotes the incidence rate from bone marrow as the source, B from peripheral blood and C from cord blood. A and B both do not show that the TT genotype has a statistical significance in the occurrence of CMV (P = 0.722 and P = 0.175 respectively). C however, shows statistical significance (P = 0.008) in the occurrence of CMV for TT genotypes compared to other genotypes.
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